Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 276

Chris Cuffe: investing with Hearts and Minds

It’s not often that an opportunity presents itself where you can both make money and contribute to a good cause. A new listed investment company (LIC), Hearts and Minds Investment Limited (Hearts and Minds), of which I am Chairman, is one such opportunity.

Hearts and Minds is seeking to raise up to $500 million and list on the ASX in November (ASX:HM1). There are many LICs on the market, but what makes Hearts and Minds different from most is that it has a charitable goal.

Of course, an objective of Hearts and Minds is to make money for investors, but Hearts and Minds will forego any investment fees and instead make donations to designated medical research charities every six months. Also, the Hearts and Minds Board and Investment Committee members have waived rights to be paid director and committee fees. The lead arranger and brokers for the Offer have waived broker management fees.

The donation amount for each six-month period will be equal to 1.5% per annum of the average monthly NTA (net tangible assets) for the previous half-year. If the portfolio increases in value, the donation amount will increase.

Investment in medical research is critical, and this field has historically provided instances of strong returns. For every dollar invested in medical research, it is estimated that an average of $2.17 in health benefits is returned.

High-conviction picks in a concentrated portfolio

Aside from the charitable goal, the Hearts and Minds LIC is aimed at investors seeking exposure to a high-conviction portfolio of global equities.

The portfolio will be concentrated, with only about 25 stocks. Hearts and Minds will take long-only positions on Australian and international listed securities based on the highest conviction ideas from two groups of fund managers:

  • 40% of the portfolio will be held in about 10 securities based on the recommendations of fund managers who present at the yearly Sohn Hearts and Minds Investment Conference.
  • 60% of the portfolio will be held in about 15 securities based on the quarterly recommendations of five leading fund managers: Caledonia, Cooper Investors, Magellan, Paradice Investment Management and Regal Funds Management.

Hearts and Minds has been established following the Sohn Hearts and Minds Investment Conference, which is in its third year now. At this Conference, industry professionals share their expertise and provide their best investment ideas. It sells tickets and the proceeds go to medical research. It has raised $8 million to date.

The Hearts and Minds IPO thus provides shareholders with an opportunity to benefit from the expertise of each fund manager, some of whom are not readily accessible to retail investors.

Investors will also benefit from having a portfolio that is not concentrated on the philosophy or investment thesis of just one fund manager.

Initially, the designated charities are: Victor Chang Cardiac Research Institute; Black Dog Institute; The Brain and Mind Centre, Sydney University; Charlie Teo Foundation; The Children’s Hospital at Westmead; Florey Institute of Neuroscience & Mental Health; Centre of Human Psychopharmacology, Swinburne University; Multiple Sclerosis Research Australia; Orygen; and Royal Prince Alfred Hospital, Research.

Strong momentum with more than $225 million in commitments

Hearts and Minds has already attracted strong support with numerous cornerstone family investors having already committed more than $185 million. Members of the Board and the Investment Committee and their associates are committing more than $40 million to the Offer. Heats and Minds will not accept oversubscriptions.

The Board has a strong mix of business, social enterprise and philanthropic experience.  It includes Ariadne Australia director Dr Gary Weiss, Wilson Asset Management founder Geoff Wilson. UBS Australia CEO Matthew Grounds is a proposed director.

The Board of Hearts and Minds has appointed Rory Lucas as the CEO. Rory has worked in the Australian and global equity markets for nearly 30 years. Rory’s specialty is in trade execution, portfolio construction and risk management. His previous roles include managing funds at Rothschild Australia Asset Management, a senior equity facilitation role at UBS, and trading and execution roles at the Commonwealth Bank of Australia.

The IPO opens on Monday 15 October 2018 and is expected to close on 6 November 2018. Shares in Hearts and Minds are expected to start trading on the ASX on 21 November under the code HM1.

This is an investment supported by some of the best and brightest fund managers and investors in the nation, with a genuinely worthwhile philanthropic goal.

I encourage you to read the Prospectus. Applications under the general Offer can be made by completing the application form attached to the Prospectus or online through the application form accompanying the electronic Prospectus. Applicants under the broker firm offer should contact their broker for application details. The Lead Arrangers for the Offer are CommSec, NAB and Crestone. Brokers include Bell Potter, Evans Dixon, JB Were, On-Market Book Builds, Ord Minnett, Paterson, Shaw and Partners, Taylor Collison and Wilsons.

Watch the video of my introduction to the Hearts and Minds Investments Limited Offer, including some of the medical work that will benefit.

 

Chris Cuffe is Chairman of Hearts and Minds Investment Limited and Founder and Portfolio Manager of Third Link Growth Fund. He is also a Co-founder of Cuffelinks. This information provided is general and does not constitute personal financial, tax or legal advice. Any participation in the Offer is subject to disclaimers in the Prospectus.

View Chris Cuffe's appearance on ABC's The Business program here.

Download Independent Investment Research's IPO Research Report on HM1 here.

  •   15 October 2018
  • 3
  •      
  •   
3 Comments
Chris
October 18, 2018

Well done, Chris, another project with no personal financial reward for you. Don’t know how you manage your wide portfolio, excellent time management I think.

Penny
November 02, 2018

Hi Chris,
I was excited to read more about the “Hearts and Minds” LIC as I am always looking for ethical investments. However I was dismayed to see that only one of the designated charities ( Black Dog Institute) do not participate in animal experimentation. All the others would be responsible for the more than 10 million animals that are experimented on every year in Australia, not only laboratory animals but dogs ( 7,205 in 2015), cats ( 2,780) and primates ( 382 in 2015). And of these, in 2015, 24,920 animals were used in the ‘Death as the end point” category of experiments, which are very nasty.
Now I know most of the public would say we need to experiment on animals to improve human and animal health and that it is a necessary “ evil”. However more and more studies are showing that the extrapolation of data from animals to humans can be dangerously misleading due to anatomic, genetic and metabolic differences. This is especially the case with drug research where 95% of drugs that enter clinical trials do not make it to the market, despite all promise of a breakthrough and the unnecessary suffering of hundreds of thousands of animals used to develop them.
As an example of your charities, both Sydney Uni and Royal Prince Alfred have used baboons to test radioactive substances, University of Sydney have been using marmosets in brain and vision experiments, this research involves the animals being placed in a skull frame, undergoing a craniotomy and having electrodes inserted into their brains while still alive.
But back to an investment in “Hearts and Minds”
A survey conducted by Nexus Research in April 2018 found that 59% of people would not donate to a health or medical research charity if they knew it was funding animal experimentation. I do hope you and your investors give consideration to , and become informed about, how much of your funds are contributing to the inhumane suffering of sentient individuals. Had you a good selection of medical charities that do not use animals and who recognise and embrace new ,scientifically valid technologies and methods that are specific to humans, I would have been keen to invest.
There is a list of humane charities available via Humane Research Australia, if any one is interested.
Thanks for opportunity to comment.

Brett
November 23, 2018

Penny, don't invest then. If we applied the philosophy you state above generally there would be no scientific research. I suppose you support experimenting on humans and think that vaccines don't work.

 

Leave a Comment:

RELATED ARTICLES

Why LIC discount harvesting is a buy-and-hold decision

Listed Investment Company deals for 2019

The missing 30%: how LIC returns are understated, and why it matters

banner

Most viewed in recent weeks

Indexation implications – key changes to 2026/27 super thresholds

Stay on top of the latest changes to superannuation rates and thresholds for 2026, including increases to transfer balance cap, concessional contributions cap, and non-concessional contributions cap.

The refinery problem: A different kind of energy crisis in 2026

The Strait of Hormuz closure due to US-Iran conflict severely disrupted global energy supply chains. While various emergency measures mitigated the crude impact, the refined product market faces unprecedented stress.

The missing 30%: how LIC returns are understated, and why it matters

The perceived underperformance of LICs compared to ETFs is due to existing comparison data excluding crucial information, highlighting the need for proper assessment and transparent reporting.

Little‑known government scheme can help retirees tap into $3 trillion of housing wealth

The Home Equity Access Scheme in Australia allows older homeowners to tap into their home equity for retirement income, yet remains underused due to lack of awareness and its perceived complexity.

Origins of the mislabeled capital gains tax ‘discount’

Debate over the CGT discount is intensifying amid concerns about intergenerational equity and housing affordability. This analysis shows that the 'discount' does not necessarily favor property investors.

Div 296 may mean your estate pays tax on assets your beneficiaries never receive

The new super tax, applying from 1 July, introduces more than just a higher rate on large balances. It brings into focus a misalignment between where wealth sits and where the tax on that wealth ultimately falls.

Latest Updates

The ultimate superannuation EOFY checklist 2026

Here is a checklist of 28 important issues you should address before June 30 to ensure your SMSF or other super fund is in order and that you are making the most of the strategies available.

Retirement

Two months into retirement

A retirement researcher's take on retirement and her focus on each of her six resource buckets to stay engaged during the transition and beyond.

Superannuation

Markets have always delivered for super fund members. What if they don’t?

What happens if market resilience in the face of ongoing geopolitical tensions ends? Potential decade-long market weakness shows the need for contingency planning.

Retirement

We tend to spend less in retirement …

Studies show that a drop in expendure during retirement leads to a happier retirement. But when costs ramp up again later in life, it's a guaranteed income that makes spending more hurt less.

Shares

Can you value a share just using dividends?

A cow for her milk, a stock for her dividends. Investors are too quick to dismiss this valuation technique. 

Property

The 25-year property trust default is being questioned

The 33% CGT discount rate being floated isn’t random. It sits at the structural break-even between trust and company for the multi-property cohort. That’s driving the conversation we’re hearing now.

Investment strategies

Are active managers bringing a knife to a gunfight?

How passive investing has permanently changed market structure — and why sophisticated tools are now the price of survival.

Sponsors

Alliances

© 2026 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.